Literature DB >> 12225644

Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C.

Robert B Villanueva1, Norbert Brau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225644     DOI: 10.1089/105072502760258730

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  6 in total

1.  IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms.

Authors:  Nagako Akeno; Eric P Smith; Mihaela Stefan; Amanda K Huber; Weijia Zhang; Mehdi Keddache; Yaron Tomer
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

Review 2.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 3.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

4.  Lanreotide treatment in a patient with interferon-associated Graves' ophthalmopathy.

Authors:  Deng-Huang Su; Ying-Chun Chang; Shu-Lang Liao; Tien-Chun Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09-28       Impact factor: 3.117

Review 5.  Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis.

Authors:  Chandrasekharan Nair Kesavachandran; Frank Haamann; Albert Nienhaus
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

6.  The influence of hepatitis C infection and interferon-alpha therapy on thyrotropin blocking and stimulating autoantibodies in Graves' ophthalmopathy: a case report.

Authors:  Huy A Tran; Glenn Em Reeves
Journal:  Thyroid Res       Date:  2009-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.